This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): TC-2696
Description: TC-2696 is a small molecule that demonstrated pain-relieving effects in models of acute, chronic and inflammatory nociceptive pain and of neuropathic pain with comparable or higher potency in preclinical animal models than morphine or indomethacin.
In the preclinical in vitro studies of TC-2696, the compound was found to be a potent activator of the a4ß2 neuronal nicotinic receptor (NNR) which avoided interaction with nicotinic receptors in the muscles and ganglia that are associated with side effects. In preclinical animal studies, TC-2696 did not result in tolerance following repeated administration.
In July 2007, GlaxoSmithKline and Targacept announced a strategic alliance to discover, develop and market novel therapeutics that selectively target specified neuronal nicotinic receptors (NNRs). The alliance includes TC-2696. Targacept has retained an option to co-promote TC-2696 for pain to specialists and hospital-based physicians in the United States.
Targacept and Catalyst
In March 2015, Targacept and Catalyst Biosciences jointly announced that they have entered into a definitive agreement to merge the two companies. The combined entity, to be named Catalyst Biosciences, will harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases.
In March 2015, Targacept and Catalyst entered into an amendment to the definitive agreement to merge the two companies.
Partners: GlaxoSmithKline plc
Pink Sheet GSK and Targacept partners in pain
Additional information available to subscribers only: